miRNA (microribonucleic acid) biomarkers and detection kit for ovarian cancer diagnosis
A biomarker and ovarian cancer technology, applied in the detection/testing of microorganisms, DNA/RNA fragments, recombinant DNA technology, etc., can solve the problems of shallow understanding of miRNA and urgent need for further investigation of ovarian cancer
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0021] Example 1: Screening of differential miRNAs in ovarian cancer tissues
[0022] 1 Objects and methods
[0023] 1.1 Specimen source
[0024] After obtaining the patient’s informed consent, 8 pairs of postoperative specimens from patients with ovarian cancer confirmed by pathology in Jiangsu Provincial People’s Hospital from April 2013 to June 2014 were collected, including cancer tissue specimens and paired paracancerous tissues that were more than 3 cm away from the cancer tissue. All patients had not received chemotherapy and radiotherapy before operation.
[0025] 1.2 Main instruments and equipment
[0026] Desktop centrifuge: Eppendorf Minispin (USA) Eppendorfcentrifuge5810R (USA)
[0027] Nucleic acid concentrator: Eppendorfconcentrator5301 (USA)
[0028] Ultraviolet spectrophotometer: DU640, balance (Beckman company product)
[0029] Ultraviolet crosslinking instrument: GSGENELINKERUVChamber (product of BIO-RAD company)
[0030] Water bath (product of Memert c...
Embodiment 2
[0100] Example 2: Serological analysis of differential miRNAs in ovarian cancer tissues
[0101] 1 Objects and methods
[0102] 1.1 Specimen source
[0103] After obtaining the informed consent of the patients, 6ml of fasting venous blood in the morning from May 2013 to March 2014 was collected from 165 patients with pathologically diagnosed ovarian cancer and 120 healthy people in Jiangsu Provincial People's Hospital as a control. All ovarian cancer patients were diagnosed for the first time, and had not undergone surgery, radiotherapy or chemotherapy before blood collection. The 120 healthy control groups were age-matched healthy people without malignant tumors or other diseases.
[0104] 1.2 Serum sample collection and processing
[0105] Draw 6ml of fasting venous blood in the morning and put it in a tube without anticoagulant, let it stand for 30 minutes, centrifuge at 1300g (or 4000rpm) at 4°C for 15 minutes, take the upper serum and divide it into RNase-freeEP tubes ...
Embodiment 3
[0154] Embodiment 3: receiver operating characteristic curve (ROC) analysis
[0155] A ROC curve was constructed to compare the diagnostic ability of five serum miRNAs to distinguish ovarian cancer patients from healthy controls. The areas under the ROC curve (AUC) of the five miRNAs were: has-miR-193b-3p, 0.840 (95% confidence interval: 0.760-0.920); has-miR-155-5p, 0.819 (95% confidence interval: 0.736-0.902 ); has-miR-145-5p, 0.814 (95% confidence interval: 0.734-0.894); has-miR-132-3p, 0.843 (95% confidence interval: 0.765-0.920); has-miR-143-3p, 0.738 (95% confidence interval: 0.644-0.832). Under the optimal cutoff value, the sensitivity and specificity of miRNA are as follows: has-miR-193b-3p, respectively 83.3% and 82.7%; has-miR-155-5p, respectively, 64.8% and 94.2%; has- miR-145-5p, respectively 90.7% and 61.5%; has-miR-132-3p, respectively, 70.4% and 82.5%; has-miR-143-3p, respectively, 67.3% and 74.1%. The combined AUC of these five miRNAs can reach 0.973, and th...
PUM
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com